These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 8371589)

  • 1. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
    Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ
    Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
    Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
    Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
    Klingemann HG; Deal H; Reid D; Eaves CJ
    Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2-activated cord blood mononuclear cells.
    Derzic S; Slone V; Sender L
    Cytotherapy; 2005; 7(5):408-16. PubMed ID: 16236630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
    Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
    Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
    Verma UN; Bagg A; Brown E; Mazumder A
    Bone Marrow Transplant; 1994 Feb; 13(2):115-23. PubMed ID: 8205079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
    Wong EK; Eaves C; Klingemann HG
    Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemopoietin-1 activity of interleukin-1 (IL-1) on acute myeloid leukemia colony-forming cells (AML-CFU) in vitro: IL-1 induces production of tumor necrosis factor-alpha which synergizes with IL-3 or granulocyte-macrophage colony-stimulating factor.
    Delwel R; van Buitenen C; Salem M; Oosterom R; Touw I; Löwenberg B
    Leukemia; 1990 Aug; 4(8):557-60. PubMed ID: 2201834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients.
    Cortelezzi A; Sarina B; Cattaneo C; Pomati M; Silvestris I; Soligo D; Calori R; Di Stefano M; Hu C; Monza M; Radelli L; Maiolo AT
    Leukemia; 1996 Jul; 10(7):1181-9. PubMed ID: 8684000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Killing effect of interleukin-2 and interferon-alpha activated leukemic bone marrow in remission on K562 leukemic cells.
    Li C; Yan W; Hao Y; Han M; Qiu L; Liu H; Han J; Li X; Feng S
    Chin Med J (Engl); 1999 Jan; 112(1):53-5. PubMed ID: 11593642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term liquid marrow cultures are supported by a mixture of haematopoietic cytokines but do not purge for acute myeloid or lymphoid leukemic marrow cells.
    Johnsen HE; Gaarsdal E; Jensen L; Philip P; Hansen NE
    Leukemia; 1993 Sep; 7(9):1402-8. PubMed ID: 8371591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
    Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
    Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
    Margolin KA; Wright C; Forman SJ
    Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma.
    Gajewski TF; Fitch FW
    J Immunol; 1990 Jan; 144(2):548-56. PubMed ID: 2104898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer (NK) cell activity in human long-term bone marrow cultures (LTBMC): effects of interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on the progenitor cells.
    Sitnicka E; Hansson M
    Immunology; 1992 Jun; 76(2):292-8. PubMed ID: 1634251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.